ALSPW Spineway SAS

Reverse stock split

Reverse stock split

Press release        Ecully, February 29, 2024 – 6:00 p.m.



Effective date of the Spineway reverse stock split

Spineway announces the completion of the reverse stock split by exchanging 1 new share of 4.00 euros par value for 2,000 old shares of 0.002 euro par value. This transaction, which was carried out pursuant to a decision by the Company's shareholders at an Extraordinary General Meeting held on November 10, 2023, took effect on February 27, 2024.

The old Spineway shares with a par value of €0.002 (ISIN code: FR001400BVK2) were delisted from the Euronext Growth market after the close of the market on February 26, 2024 and were replaced with the new Spineway shares with a par value of €4.00 (ISIN code: FR001400N2P2) on February 27, 2024. The mnemonic code (ALSPW) remains unchanged.

As at 27 February 2024, Spineway's share capital comprised 832,962 shares with a par value of €4.00 each.

It should be noted that, as of February 26, 2024, after the close of the market, the new shares that could not be allotted individually and which correspond to fractional rights will be sold automatically by block on the market by financial intermediaries. The financial intermediaries will make the proceeds of the sale available to their shareholder clients within 30 days from February 26, 2024. For more information on the reverse split, shareholders are invited to consult the notice of reverse split published in the , and available on the Company's website () and the press release published on also available on the Company's website.

Increase in share capital

Following conversions of Negma Group Ltd bonds between 22 January 2024 and 9 February 2024, the Company's Board of Directors, meeting on 29 February 2024, recorded the creation of 1,191,228,073 new ordinary shares and an increase in the share capital of a nominal amount of €2,382,456.15. As these conversions took place during the consolidation period, the new shares issued were taken into account in the exchange transactions.

Reduction of the share capital

Subsequent to the reverse stock split, the Company's Board of Directors decided on 29 February 2024 to reduce the share capital by reducing the par value of the Company's shares1. This purely technical operation has no impact on the value of the Company's stock value, nor on the number of shares in circulation. Thus, after this operation, the Company's share capital is still composed of 832,962 ordinary shares, i.e. the number of shares making up the share capital following the above-mentioned reverse stock split, effective since 27 February 2024.

Next events:

March 25, 2024 – Annual General Meeting

April 16, 2024 – Q1 2024 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Contacts :

SPINEWAY GROUP



Shareholder - services line



Available Tuesday through Thursday



+33 (0)806 70 60 60
ELIGIBLE PEA / PME





ALSPW





Euronext Growth

AELIUM



Finance & Communication







Investor relations



Solène Kennis






1 The legal par value of one share is thus reduced from 4.00 euros to 0.045 euro and the share capital to 37,483.29 euros.

Attachment



EN
29/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accéléra...

SPINEWAY : Chiffre d’affaires annuel 2025 de 12,4 ME avec une accélération des ventes au T4 2025 (+34%) Ecully, le 13 janvier 2026 – 18h30 SPINEWAY Chiffre d’affaires annuel 2025 de 12,4 M€ avec une accélération des ventes au T4 2025 (+34%) En milliers d’euros20252024Variation en %CA 1er semestre5 5736 535- 15%CA 2ème semestre6 8575 415+ 27%CA annuel12 43011 950+ 4% Données consolidées non auditées Au dernier trimestre 2025, Spineway, spécialiste des implants innovants pour le traitement des pathologies de la colonne vertébrale (rachis), a bénéficié d’une accélération des ventes sur l...

 PRESS RELEASE

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sal...

SPINEWAY : 2025 revenue of €12.4 million,  with an acceleration of sales in Q4 2025 (+34%) Ecully, January 13, 2026 – 6:30 p.m. SPINEWAY 2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%) In thousands of euros20252024Change as a %H1 revenue5,5736,535-15%H2 revenue6,8575,415+27%Full-year revenue12,43011,950+4% Unaudited consolidated data In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders d...

 PRESS RELEASE

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ES...

SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie  Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie  Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce la conclusion d'un accord avec Evolution Surgical, pour la distribution exclusive de ses prothèses discales ESP en Australie à partir du 25 octobre 2025. Orthotech, l’ancien distributeur sur cette zone, assurera en collaboratio...

 PRESS RELEASE

Spineway : Revenue growth in the third quarter

Spineway : Revenue growth in the third quarter Ecully, October 14, 2025 – 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575   +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M revenue8,6189,110      -5% Unaudited consolidated data The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, benefited, in line with its expectations, from a deferral of orders from major accounts to the third quarter of 2025 and generated revenue of €3.0 million over the period, up from €2.6 millio...

 PRESS RELEASE

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre

SPINEWAY : Croissance du chiffre d’affaires au 3ème trimestre Ecully, le 14 octobre 2025 – 18h30 SPINEWAYCroissance du chiffre d’affaires au 3ème trimestre En milliers d’euros20252024Variationen %CA 3ème trimestre3 0452 575   + 18%CA 2ème trimestre2 7453 465- 21%CA 1er trimestre2 8283 070      - 8%CA 9 mois8 6189 110       - 5% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a bénéficié, conformément à ses anticipations, d’un report des commandes de grands comptes sur le 3ème trimes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch